Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aravive, Inc.VSAR · Entity 114535 | COO and CFO | October 19, 2017 | October 23, 2017 |
| CRESCENT BIOPHARMA, INC.CBIO · Entity 5255 | Director · Chief Executive Officer | September 16, 2026 | September 18, 2026 |
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Director · CEO & President | March 08, 2024 | March 13, 2024 |
| Kaleido Biosciences, Inc.KLDO · Entity 129745 | See Remarks | March 04, 2019 | March 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aravive, Inc.
Report date October 19, 2017 · Filed October 23, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 201,269 |
Reported balance
After 2017-10-19 transaction · row 1
1 source rowRow 1 · 2017-10-19 · Sale · Disposed 1,326 · Balance 201,269 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant.
CRESCENT BIOPHARMA, INC.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 271,765 |
Ending reported balance
After 2026-09-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-16 · Sale · Disposed 1,610 · Balance 279,602 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 2 · 2026-09-18 · Sale · Disposed 7,837 · Balance 271,765 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
F2: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Dyne Therapeutics, Inc.
Report date March 08, 2024 · Filed March 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 708,316 |
Reported balance
After 2024-03-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-03-08 · Exercise / conversion · Acquired 153,931 · Balance 708,316 |
| Common StockSEC Table I · non-derivative | Direct | 917,728 |
Reported balance
After 2024-03-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-03-08 · Exercise / conversion · Acquired 209,412 · Balance 917,728 |
| Common StockSEC Table I · non-derivative | Direct | 715,490 |
Reported balance
After 2024-03-08 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2024-03-08 · Sale · Disposed 202,238 · Balance 715,490 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.20 to $26.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 554,820 |
Reported balance
After 2024-03-08 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2024-03-08 · Sale · Disposed 160,670 · Balance 554,820 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $27.18, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 554,385 |
Reported balance
After 2024-03-08 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2024-03-08 · Sale · Disposed 435 · Balance 554,385 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.49, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 604,385 |
Reported balance
After 2024-03-11 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2024-03-11 · Exercise / conversion · Acquired 50,000 · Balance 604,385 |
| Common StockSEC Table I · non-derivative | Direct | 564,313 |
Reported balance
After 2024-03-11 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2024-03-11 · Sale · Disposed 40,072 · Balance 564,313 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.75, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 554,385 |
Reported balance
After 2024-03-11 transaction · row 8
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 8 · 2024-03-11 · Sale · Disposed 9,928 · Balance 554,385 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.01 to $26.10, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 546,616 |
Reported balance
After 2024-03-11 transaction · row 9
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 9 · 2024-03-11 · Sale · Disposed 7,769 · Balance 546,616 F6: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.22 to $26.18, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 537,998 |
Reported balance
After 2024-03-11 transaction · row 10
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 10 · 2024-03-11 · Sale · Disposed 8,618 · Balance 537,998 F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.68 to $26.05, inclusive. F9: Includes 513,913 unvested RSUs. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.54 · Expires 2030-07-30 | Direct | 0 |
Reported balance
After 2024-03-08 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-03-08 · Exercise / conversion · Disposed 153,931 · Balance 0 F10: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.54 · Expires 2030-07-30 | Direct | 133,269 |
Reported balance
After 2024-03-08 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-03-08 · Exercise / conversion · Disposed 209,412 · Balance 133,269 F11: The option was granted on July 31, 2020. The shares underlying the option vest over four years in sixteen equal installments beginning on October 31, 2020. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.54 · Expires 2030-07-30 | Direct | 83,269 |
Reported balance
After 2024-03-11 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2024-03-11 · Exercise / conversion · Disposed 50,000 · Balance 83,269 F11: The option was granted on July 31, 2020. The shares underlying the option vest over four years in sixteen equal installments beginning on October 31, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.20 to $26.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $27.18, inclusive.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.49, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.75, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.01 to $26.10, inclusive.
F6: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.22 to $26.18, inclusive.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.68 to $26.05, inclusive.
F9: Includes 513,913 unvested RSUs.
F10: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.
F11: The option was granted on July 31, 2020. The shares underlying the option vest over four years in sixteen equal installments beginning on October 31, 2020.
Kaleido Biosciences, Inc.
Report date March 04, 2019 · Filed March 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2029-03-04 | Direct | 80,000 |
Reported balance
After 2019-03-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-04 · Grant · Acquired 80,000 · Balance 80,000 F1: 25% of this option shall vest on January 23, 2020, with the remainder vesting in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest on January 23, 2020, with the remainder vesting in 12 equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 18, 2026 20:02 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | SaleOrdinary Shares | 7,837 | $16.71 | $130,956.27 |
DisclosureSEC source: 0001628280-26-062701 · wk-form4_1789761722.xml · nonDerivative · entry 2 Brumm Joshua T · CIK 0001528826 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 271,765 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2 · price: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 20:02 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | SaleOrdinary Shares | 1,610 | $17.90 | $28,819.00 |
DisclosureSEC source: 0001628280-26-062701 · wk-form4_1789761722.xml · nonDerivative · entry 1 Brumm Joshua T · CIK 0001528826 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 279,602 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2 · price: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:01 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | SaleOrdinary Shares | 42,305 | $17.99 | $761,066.95 |
DisclosureSEC source: 0001628280-26-044884 · wk-form4_1782244898.xml · nonDerivative · entry 1 Brumm Joshua T · CIK 0001528826 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,212 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:46 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantStock Option (Right to Buy) · Derivative | 180,467 | $0.00 Strike: $13.21 | $0.00 |
DisclosureSEC source: 0001628280-25-057683 · wk-form4_1766007988.xml · derivative · entry 3 Brumm Joshua T · CIK 0001528826 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,467 Underlying: Ordinary Shares · 180,467 shares Expires 2035-12-15 F2 · derivative.exercise_date: This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:46 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantOrdinary Shares | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-057683 · wk-form4_1766007988.xml · nonDerivative · entry 2 Brumm Joshua T · CIK 0001528826 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,517 F1 · price: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:46 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantOrdinary Shares | 45,117 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-057683 · wk-form4_1766007988.xml · nonDerivative · entry 1 Brumm Joshua T · CIK 0001528826 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,517 F1 · price: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:35 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantStock Option (Right to Buy) · Derivative | 345,672 | $0.00 Strike: $13.17 | $0.00 |
DisclosureSEC source: 0001628280-25-056331 · wk-form4_1765402538.xml · derivative · entry 1 Brumm Joshua T · CIK 0001528826 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,672 Underlying: Ordinary Shares · 345,672 shares Expires 2035-12-08 F1 · derivative.exercise_date: This option represents a right to purchase shares of the Issuer's ordinary shares and vests in 48 approximately equal monthly installments that commenced on December 8, 2025. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 01:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-24-030479 · ownership.xml · derivative · entry 13 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,269 Underlying: Common Stock · 50,000 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option vest over four years in sixteen equal installments beginning on October 31, 2020. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 01:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 8,618 | $25.93 | $223,464.74 |
DisclosureSEC source: 0000950170-24-030479 · ownership.xml · nonDerivative · entry 10 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 537,998 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.68 to $26.05, inclusive. F9 · balance_after: Includes 513,913 unvested RSUs. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 01:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 7,769 | $26.12 | $202,926.28 |
DisclosureSEC source: 0000950170-24-030479 · ownership.xml · nonDerivative · entry 9 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 546,616 F6 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.22 to $26.18, inclusive. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 01:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 9,928 | $26.10 | $259,120.80 |
DisclosureSEC source: 0000950170-24-030479 · ownership.xml · nonDerivative · entry 8 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 554,385 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.01 to $26.10, inclusive. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 01:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 40,072 | $25.42 | $1,018,630.24 |
DisclosureSEC source: 0000950170-24-030479 · ownership.xml · nonDerivative · entry 7 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 564,313 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.75, inclusive. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 01:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 50,000 | $5.54 | $277,000.00 |
DisclosureSEC source: 0000950170-24-030479 · ownership.xml · nonDerivative · entry 6 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 604,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 209,412 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-24-030479 · ownership.xml · derivative · entry 12 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,269 Underlying: Common Stock · 209,412 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option vest over four years in sixteen equal installments beginning on October 31, 2020. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 153,931 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-24-030479 · ownership.xml · derivative · entry 11 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 153,931 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 435 | $27.38 | $11,910.30 |
DisclosureSEC source: 0000950170-24-030479 · ownership.xml · nonDerivative · entry 5 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 554,385 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.49, inclusive. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 160,670 | $26.72 | $4,293,102.40 |
DisclosureSEC source: 0000950170-24-030479 · ownership.xml · nonDerivative · entry 4 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 554,820 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $27.18, inclusive. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 202,238 | $25.30 | $5,116,621.40 |
DisclosureSEC source: 0000950170-24-030479 · ownership.xml · nonDerivative · entry 3 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 715,490 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.20 to $26.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 209,412 | $5.54 | $1,160,142.48 |
DisclosureSEC source: 0000950170-24-030479 · ownership.xml · nonDerivative · entry 2 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 917,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 153,931 | $5.54 | $852,777.74 |
DisclosureSEC source: 0000950170-24-030479 · ownership.xml · nonDerivative · entry 1 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 708,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 01:57 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 9,086 | $25.85 | $234,873.10 |
DisclosureSEC source: 0000950170-24-029616 · ownership.xml · nonDerivative · entry 1 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 554,385 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.84 to $26.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 530,300 unvested RSUs. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 02:38 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 36,637 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-24-024300 · ownership.xml · derivative · entry 9 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 342,681 Underlying: Common Stock · 36,637 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 02:38 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 57,843 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-24-024300 · ownership.xml · derivative · entry 8 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,500 Underlying: Common Stock · 57,843 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 02:38 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,414 | $29.70 | $41,995.80 |
DisclosureSEC source: 0000950170-24-024300 · ownership.xml · nonDerivative · entry 6 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 563,471 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.58 to $29.88, inclusive. F1 · balance_after: Includes 530,300 unvested RSUs. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 02:38 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 74,090 | $29.23 | $2,165,650.70 |
DisclosureSEC source: 0000950170-24-024300 · ownership.xml · nonDerivative · entry 5 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 564,885 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.56 to $29.56, inclusive. F1 · balance_after: Includes 530,300 unvested RSUs. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 02:38 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 18,976 | $28.25 | $536,072.00 |
DisclosureSEC source: 0000950170-24-024300 · ownership.xml · nonDerivative · entry 4 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 638,975 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.48, inclusive. F1 · balance_after: Includes 530,300 unvested RSUs. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 02:38 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 94,480 | $5.54 | $523,419.20 |
DisclosureSEC source: 0000950170-24-024300 · ownership.xml · nonDerivative · entry 3 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 657,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 530,300 unvested RSUs. Read SEC document |
| February 29, 2024 Filed Mar 2, 2024 02:38 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 5,520 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-24-024300 · ownership.xml · derivative · entry 7 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,343 Underlying: Common Stock · 5,520 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024. Read SEC document |
| February 29, 2024 Filed Mar 2, 2024 02:38 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 5,520 | $27.50 | $151,800.00 |
DisclosureSEC source: 0000950170-24-024300 · ownership.xml · nonDerivative · entry 2 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 563,471 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $27.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. F1 · balance_after: Includes 530,300 unvested RSUs. Read SEC document |
| February 29, 2024 Filed Mar 2, 2024 02:38 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 5,520 | $5.54 | $30,580.80 |
DisclosureSEC source: 0000950170-24-024300 · ownership.xml · nonDerivative · entry 1 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 568,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 530,300 unvested RSUs. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:18 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GiftCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-009406 · ownership.xml · nonDerivative · entry 2 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 563,471 F1 · kind: This transaction was a charitable donation to a third party effective January 29, 2024 in which no value was received in return. F2 · balance_after: Includes 552,729 unvested RSUs. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:18 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-009406 · ownership.xml · nonDerivative · entry 1 Brumm Joshua T · CIK 0001528826 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 564,971 F1 · kind: This transaction was a charitable donation to a third party effective January 29, 2024 in which no value was received in return. F2 · balance_after: Includes 552,729 unvested RSUs. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 02:49 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-24-002280 · ownership.xml · derivative · entry 11 Brumm Joshua T · CIK 0001528826 · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,863 Underlying: Common Stock · 200,000 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 02:49 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 18,536 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-24-002280 · ownership.xml · derivative · entry 10 Brumm Joshua T · CIK 0001528826 · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,536 shares Expires 2030-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on October 12, 2020 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 02:49 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 38,301 | $19.05 | $729,634.05 |
DisclosureSEC source: 0000950170-24-002280 · ownership.xml · nonDerivative · entry 8 Brumm Joshua T · CIK 0001528826 · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 584,971 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.00 to $19.25, inclusive. F1 · balance_after: Includes 552,729 unvested RSUs. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 02:49 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 180,235 | $18.40 | $3,316,324.00 |
DisclosureSEC source: 0000950170-24-002280 · ownership.xml · nonDerivative · entry 7 Brumm Joshua T · CIK 0001528826 · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 623,272 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.93, inclusive. F1 · balance_after: Includes 552,729 unvested RSUs. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 02:49 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 200,000 | $5.54 | $1,108,000.00 |
DisclosureSEC source: 0000950170-24-002280 · ownership.xml · nonDerivative · entry 6 Brumm Joshua T · CIK 0001528826 · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 803,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 552,729 unvested RSUs. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 02:49 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 18,536 | $1.03 | $19,092.08 |
DisclosureSEC source: 0000950170-24-002280 · ownership.xml · nonDerivative · entry 5 Brumm Joshua T · CIK 0001528826 · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 603,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 552,729 unvested RSUs. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:49 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 51,183 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-24-002280 · ownership.xml · derivative · entry 9 Brumm Joshua T · CIK 0001528826 · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,536 Underlying: Common Stock · 51,183 shares Expires 2030-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on October 12, 2020 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:49 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 16,026 | $20.50 | $328,533.00 |
DisclosureSEC source: 0000950170-24-002280 · ownership.xml · nonDerivative · entry 4 Brumm Joshua T · CIK 0001528826 · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 584,971 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.50 to $20.58, inclusive. F1 · balance_after: Includes 552,729 unvested RSUs. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:49 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 19,775 | $19.03 | $376,318.25 |
DisclosureSEC source: 0000950170-24-002280 · ownership.xml · nonDerivative · entry 3 Brumm Joshua T · CIK 0001528826 · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 600,997 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.00 to $19.25, inclusive. F1 · balance_after: Includes 552,729 unvested RSUs. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:49 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 15,382 | $18.34 | $282,105.88 |
DisclosureSEC source: 0000950170-24-002280 · ownership.xml · nonDerivative · entry 2 Brumm Joshua T · CIK 0001528826 · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 620,772 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. F1 · balance_after: Includes 552,729 unvested RSUs. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:49 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 51,183 | $1.03 | $52,718.49 |
DisclosureSEC source: 0000950170-24-002280 · ownership.xml · nonDerivative · entry 1 Brumm Joshua T · CIK 0001528826 · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 636,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 552,729 unvested RSUs. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:33 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 7,585 | $10.72 | $81,311.20 |
DisclosureSEC source: 0001209191-23-058327 · doc4.xml · nonDerivative · entry 1 Brumm Joshua T · CIK 0001528826 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 584,971 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.72 to $10.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 552,729 unvested RSUs. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:29 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 139,750 | $0.00 Strike: $10.88 | $0.00 |
DisclosureSEC source: 0001209191-23-055523 · doc4.xml · derivative · entry 2 Brumm Joshua T · CIK 0001528826 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,750 Underlying: Common Stock · 139,750 shares Expires 2033-11-14 F3 · derivative.exercise_date: This option was granted on November 15, 2023. The shares underlying the option are scheduled to vest over four years in equal monthly installments through November 15, 2027. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:29 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 358,877 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-055523 · doc4.xml · nonDerivative · entry 1 Brumm Joshua T · CIK 0001528826 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 592,556 F1 · shares: Consists of shares of Common Stock issuable under 358,877 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on February 15, 2024. F2 · balance_after: Includes 569,116 unvested RSUs. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:47 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 12,032 | $9.41 | $113,221.12 |
DisclosureSEC source: 0001209191-23-050169 · doc4.xml · nonDerivative · entry 1 Brumm Joshua T · CIK 0001528826 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,679 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 210,239 unvested RSUs. Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 23:50 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 7,672 | $10.41 | $79,865.52 |
DisclosureSEC source: 0001209191-23-049357 · doc4.xml · nonDerivative · entry 1 Brumm Joshua T · CIK 0001528826 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,711 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.09 to $10.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 236,996 unvested RSUs. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 01:22 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock Option (right to buy) · Derivative | 171,360 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001209191-23-036544 · doc4.xml · derivative · entry 12 Brumm Joshua T · CIK 0001528826 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,719 Underlying: Common Stock · 171,360 shares Expires 2023-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on October 12, 2020 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 01:22 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 187,748 | $12.61 | $2,367,502.28 |
DisclosureSEC source: 0001209191-23-036544 · doc4.xml · nonDerivative · entry 9 Brumm Joshua T · CIK 0001528826 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,383 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.18 to $13.14, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.